Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 9/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 9/20 | 0.41 |
| ▸ | ESR1 | P03372 | 3/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.37 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.37 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.37 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.37 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.37 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.36 |
| ▸ | CETP | P11597 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15042437 | 0.98 | ESR1 (0.41) | SLC6A3SLC6A4ESR1HDAC4PSEN1 | |
| SCHEMBL10178154 | 0.85 | ICMT (0.36) | ESR1HDAC4 | |
| SCHEMBL15043621 | 0.82 | SLC6A3 (0.44) | SLC6A3SLC6A4ESR1HDAC4PSEN1 | |
| SCHEMBL15043623 | 0.80 | ESR1 (0.44) | SLC6A3SLC6A4ESR1HDAC4PSEN1 | |
| SCHEMBL28984518 | 0.78 | SLC6A3 (0.44) | SLC6A3SLC6A4ESR1HDAC4PSEN1 | |
| SCHEMBL15042370 | 0.78 | HDAC4 (0.42) | SLC6A3SLC6A4ESR1HDAC4SLC6A2 | |
| SCHEMBL9359639 | 0.77 | SLC6A3 (0.43) | SLC6A3SLC6A4ESR1HDAC4SLC6A2 | |
| SCHEMBL8931548 | 0.77 | SLC6A3 (0.43) | SLC6A3SLC6A4ESR1HDAC4SLC6A2 | |
| SCHEMBL12000464 | 0.74 | SLC6A3 (0.57) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL10181551 | 0.74 | SLC6A3 (0.45) | SLC6A3SLC6A4SLC6A2CETP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8822510-B2 | Substituted 3-phenyl-1,2,4-Oxadiazole compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-02 | — | — | US | disclosed |
| US-20130158001-A1 | SUBSTITUTED 3-PHENYL-1,2,4-OXADIAZOLE COMPOUNDS | BRISTOL-MYERS SQUBIB COMPANY | 2013-06-20 | — | — | US | disclosed |
| WO-2012012477-A1 | SUBSTITUTED 3-PHENYL-1,2,4-OXADIAZOLE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158001-A1 | SUBSTITUTED 3-PHENYL-1,2,4-OXADIAZOLE COMPOUNDS | S1PR1, S1PR3, S1PR2 | SLC6A3 2766/4885SLC6A4 2698/4885ESR1 1485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.